Gary Heimberg Joins Covington's Global Public Policy Group
June 2, 2015
WASHINGTON, DC, June 2, 2015 - Gary Heimberg has joined Covington’s global public policy and government affairs group in the firm’s Washington office. Mr. Heimberg will advise the firm’s pharmaceutical and consumer health care clients on legislative and policy issues facing the pharmaceutical industry, including in the areas of intellectual property, over-the-counter medicines, vaccines, medical devices, biodefense, and Food and Drug Administration reform.
“Gary will be a tremendous asset to the firm and our clients,” said Dan Bryant, chair of Covington’s public policy and government affairs practice. “His extensive policy and legislative experience across all the life sciences issues will be invaluable as we work with clients to address the multiple legislative initiatives affecting the life sciences industry now pending in Congress.”
Mr. Heimberg has previous experience in government, private practice and the pharmaceutical industry. Most recently, he served as the director for federal government relations at GlaxoSmithKline, the multinational pharmaceutical company. Earlier in his career, Mr. Heimberg spent 14 years as a lawyer with an international firm in Washington. He also spent more than two years as a professional staff member for the U.S. Senate Committee on Labor and Human Resources.
“I am thrilled to join one of the most respected public policy teams in the nation, and to help Covington’s clients navigate and shape global policy developments,” Mr. Heimberg said.
Mr. Heimberg received a bachelor’s degree, a master’s degree and a law degree from George Washington University.
Back
